Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Acute Myocardial Infarction: Clinical Advances in Prognostic Stratification, Diagnosis, and...
share announcement

Acute Myocardial Infarction: Clinical Advances in Prognostic Stratification, Diagnosis, and Treatment

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 1783

Special Issue Editors

Dr. Matteo Armillotta

E-Mail Website
Guest Editor
1. Department of Medical and Surgical Sciences—DIMEC, University of Bologna, Bologna, Italy
2. IRCCS S. Orsola Hospital, 40138 Bologna, Italy
Interests: clinical cardiology; acute myocardial infarction; atherosclerosis; cardiac imaging; cardiac magnetic resonance
Dr. Luca Bergamaschi

E-Mail Website
Guest Editor
1. Department of Medical and Surgical Sciences—DIMEC, University of Bologna, Bologna, Italy
2. IRCCS S.Orsola Hospital, 40138, Bologna, Italy
Interests: clinical cardiology; acute myocardial infarction; non-invasive imaging; cardiac imaging
Special Issues, Collections and Topics in MDPI journals
Dr. Carmine Pizzi

E-Mail Website
Guest Editor
1. Department of Medical and Surgical Sciences—DIMEC, University of Bologna, Bologna, Italy
2. IRCCS S. Orsola Hospital, 40138 Bologna, Italy
Interests: clinical cardiology; acute myocardial infarction; chronic coronary syndrome; non-invasive imaging; preventive cardiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Acute myocardial infarction (AMI) is a major global health challenge, significantly contributing to morbidity and mortality. Recent advancements in prognostic stratification, diagnosis, and treatment of AMI have the potential to improve patient outcomes.

Accurate risk assessment, crucial for managing AMI patients, has been enhanced by biomarker research, including high-sensitivity cardiac troponins, enabling earlier and more precise stratification. Integrating clinical risk scores with these biomarkers and imaging techniques refines prognostic evaluations.

Diagnostic accuracy has significantly improved with high-sensitivity troponin assays and advanced imaging methods like coronary CT angiography (CCTA) and cardiac magnetic resonance (CMR).

Treatment strategies such as timely reperfusion therapy, antiplatelet therapy, and anticoagulant therapy, along with emerging pharmacological treatments, are essential in managing AMI cases. Intravascular imaging techniques, including optical coherence tomography (OCT) and intravascular ultrasound (IVUS), provide detailed insights into coronary lesions, facilitating personalized treatment. The integration of clinical data with advanced imaging and molecular techniques is advancing personalized medicine in AMI care.

We invite contributions to this Special Issue to share the latest research and insights on clinical advances in prognostic stratification, diagnosis, and treatment of AMI, aiming to enhance our understanding and management of this critical condition.

Dr. Matteo Armillotta
Dr. Luca Bergamaschi
Dr. Carmine Pizzi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acute myocardial infarction (AMI)
  • atherosclerosis
  • ST segment elevation myocardial infarction (STEMI)
  • non-ST elevation myocardial infarction (NSTEMI)
  • acute coronary syndrome (ACS)
  • prognosis
  • coronary CT angiography (CCTA)
  • cardiac magnetic resonance (CMR)
  • reperfusion therapy
  • antiplatelet therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 939 KiB  
Article
Intraventricular Thrombosis After Myocardial Infarction: Prognostic Evaluation in Relation to Microvascular Obstruction Extent by CMR
by Antonella Cecchetto, Francesco Zupa, Manuel De Lazzari, Angiola Bolis, Anna Baritussio, Stefano Nistri, Giorgio De Conti and Martina Perazzolo Marra
J. Clin. Med. 2025, 14(8), 2658; https://doi.org/10.3390/jcm14082658 - 13 Apr 2025
Viewed by 217
Abstract
(1) Background: There are few data on anticoagulation therapy for left ventricular (LV) thrombosis following ST-segment elevation myocardial infarction (STEMI). The aim of this study was to assess whether microvascular obstruction (MVO) extent on cardiac magnetic resonance (CMR) worsened the prognosis of [...] Read more.
(1) Background: There are few data on anticoagulation therapy for left ventricular (LV) thrombosis following ST-segment elevation myocardial infarction (STEMI). The aim of this study was to assess whether microvascular obstruction (MVO) extent on cardiac magnetic resonance (CMR) worsened the prognosis of patients with LV thrombosis receiving anticoagulation. (2) Methods: reperfused STEMI patients undergoing CMR were enrolled. Patients were divided into 4 groups according to MVO and LV thrombosis presence or absence. Occurrence of major adverse cardiac events (MACE) was evaluated during follow-up. (3) Results: 80 STEMI patients were enrolled. According to MVO and LV thrombosis, 4 subgroups were obtained: patients with MVO and LV thrombosis (21 patients, 26%); patients with MVO without LV thrombosis (28 patients, 35%); patients without MVO with LV thrombosis (6 patients, 8%); patients without MVO and LV thrombosis (25 patients, 31%). All patients with LV thrombosis were treated with anticoagulation therapy. The median time to the follow-up was 11 months. Twenty-two patients (27%) experienced MACE. LV thrombosis treated with anticoagulation was an independent predictor of MACE (hazard ratio, 2.828; 95% confidence interval, 1.205–6.638; p = 0.017) and was associated with a worse prognosis (p = 0.012), regardless of MVO (p = 0.852), at Kaplan–Meier. (4) Conclusions: Patients with LV thrombosis treated with anticoagulation after a reperfused STEMI have a worse prognosis than those without; however, MVO extent did not worsen prognosis. Full article
(This article belongs to the Special Issue Acute Myocardial Infarction: Clinical Advances in Prognostic Stratification, Diagnosis, and Treatment)
►▼ Show Figures

Graphical abstract

17 pages, 1801 KiB  
Article
Efficacy of Colchicine in Reducing NT-proBNP, Caspase-1, TGF-β, and Galectin-3 Expression and Improving Echocardiography Parameters in Acute Myocardial Infarction: A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
by Tri Astiawati, Mohammad Saifur Rohman, Titin Wihastuti, Hidayat Sujuti, Agustina Tri Endharti, Djanggan Sargowo, Delvac Oceandy, Bayu Lestari, Efta Triastuti and Ricardo Adrian Nugraha
J. Clin. Med. 2025, 14(4), 1347; https://doi.org/10.3390/jcm14041347 - 18 Feb 2025
Cited by 1 | Viewed by 659
Abstract
Background: Caspase-1 (reflects NOD-like receptor protein 3 inflammasome activity), transforming growth factor-β (TGF-β), and Galectin-3 play significant roles in post-AMI fibrosis and inflammation. Recently, colchicine was shown to dampen inflammation after AMI; however, its direct benefit remains controversial. Objectives: This study aimed to [...] Read more.
Background: Caspase-1 (reflects NOD-like receptor protein 3 inflammasome activity), transforming growth factor-β (TGF-β), and Galectin-3 play significant roles in post-AMI fibrosis and inflammation. Recently, colchicine was shown to dampen inflammation after AMI; however, its direct benefit remains controversial. Objectives: This study aimed to analyze the benefit of colchicine in reducing NT-proBNP, Caspase-1, TGF-β,and Galectin-3 expression and improving systolic–diastolic echocardiography parameters among AMI patients. Methods: A double-blinded, placebo-controlled, randomized, multicenter clinical trial was conducted at three hospitals in East Java, Indonesia: Dr. Saiful Anwar Hospital Malang, Dr. Soebandi Hospital Jember, and Dr. Iskak Hospital Tulungagung, between 1 June and 31 December 2023. A total of 161 eligible AMI subjects were randomly allocated 1:1 to colchicine (0.5 mg daily) or standard treatment for 30 days. Caspase-1, TGF-β, and Galectin-3 were tested on day 1 and day 5 by ELISA, while NT-proBNP was tested on days 5 and 30. Transthoracic echocardiography was also performed on day 5 and day 30. Results: By day 30, no significant improvements in systolic–diastolic echocardiography parameters had been shown in the colchicine group. However, colchicine reduced the level of NT-proBNP on day 30 more than placebo (ΔNT-proBNP: −73.74 ± 87.53 vs. −75.75 ± 12.44 pg/mL; p < 0.001). Moreover, colchicine lowered the level of Caspase-1 expression on day 5 and the levels of TGF-β and Galectin-3 expression on day 1. Conclusions: Colchicine can reduce NT-proBNP, Caspase-1, TGF-β, and Galectin-3 expression significantly among AMI patients. Colchicine administration was capable of reducing post-AMI inflammation, ventricular dysfunction, and heart failure but did not improve systolic–diastolic echocardiography parameters (ClinicalTrials.gov identifier: NCT06426537). Full article
(This article belongs to the Special Issue Acute Myocardial Infarction: Clinical Advances in Prognostic Stratification, Diagnosis, and Treatment)
►▼ Show Figures

Figure 1

12 pages, 2926 KiB  
Article
Impact of Admission Ward on Long-Term Outcomes in Patients with Non-ST Elevation Myocardial Infarction
by Carmi Bartal, Ranin Hilu, Hadel Alsana, Ido Peles, Gal Tsaban, Miri Merkin, Gabriel Rosenstein, Aref El-Nasasra, Hezzy Shmueli, Yigal Abramowitz, Carlos Cafri, Doron Zagher and Edward Koifman
J. Clin. Med. 2025, 14(4), 1284; https://doi.org/10.3390/jcm14041284 - 15 Feb 2025
Viewed by 387
Abstract
Background: Patients presenting with non-ST elevation myocardial infarction (NSTEMI) are often admitted to medical wards. We aimed to evaluate the impact of the admitting department on long-term outcomes. Methods: Patients admitted to a large tertiary center were categorized according to the [...] Read more.
Background: Patients presenting with non-ST elevation myocardial infarction (NSTEMI) are often admitted to medical wards. We aimed to evaluate the impact of the admitting department on long-term outcomes. Methods: Patients admitted to a large tertiary center were categorized according to the admission ward, either the intensive cardiac care unit (ICCU) or internal medicine department (IMD). We compared major adverse cardiovascular events (MACEs), a composite of all-cause death, recurrent myocardial infarction (MI), and revascularization, along with the individual components of MACE, between the two groups during a long-term follow-up. Results: A total of 11,779 NSTEMI patients were included, with 4522 admitted to the ICCU and 7257 to the department of internal medicine. Patients admitted to the ICCU had lower systolic blood pressure, higher troponin levels and lower left ventricular ejection fraction (LVEF) compared to those in the IMD group, indicating greater initial clinical severity. Although patients admitted to the ICCU experienced a significantly higher rate of in-hospital complications, there were no significant differences in the incidence of in-hospital deaths between the two groups. During 5-year follow-up, NSTEMI patients initially admitted to the ICCU had significantly lower rates of mortality and MACEs. The estimated hazard ratio for 5-year MACE and 5-year mortality rates for NSTEMI patients admitted to the IMD vs. those admitted to the ICCU were 2.03 (95% CI, 1.04–3.34) and 2.5 (95% CI, 1.10–4.38), respectively. Conclusions: NSTEMI patients admitted to the ICCU experienced lower long-term mortality and MACE rates. These findings support the management of NSTEMI patients in cardiac wards and warrant further research into the reasons for the improved outcome. Full article
(This article belongs to the Special Issue Acute Myocardial Infarction: Clinical Advances in Prognostic Stratification, Diagnosis, and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop